DexCom Inc (DC4.HA)
| Previous Close | 105.66 |
| Open | 106.70 |
| Bid | 105.46 x N/A |
| Ask | 106.24 x N/A |
| Day's Range | 106.70 - 106.70 |
| 52 Week Range | 71.37 - 130.20 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.
SAN DIEGO, June 27, 2024--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be
- Business Wire
Dexcom Expands AID Partnership Into The Netherlands
EDINBURGH, Scotland, June 20, 2024--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,00
- Business Wire
Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
SAN DIEGO, June 20, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando.
